TITLE

1. Participants TITLE Participant information INTRODUCTION ANALOGUE DESIGN • Hypothesis • sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. • Objective • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet • Lorem Ipso Facto Ipsum Dolor (vMIP-II) • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto • Lorum ipsum dolor sit amet ipso facto. [7] • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto[8] • Ipso Facto L • Lorem ipsum dolor sit amet L (Figure 3) Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto • Lorum ipsum dolor sit amet ipso facto.[9] • Lorem Ipsum Dolor L • Lorum ipsum dolor sit amet ipso facto x = 1-2, 4-18 • Lorum ipsum dolor sit amet ipso facto[9] Figure 4. CXCR4 Affinity Change • Lorem ipsum dolor sit amet ipso facto.Lorem • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto[8] BACKGROUND • Lorem ipsum dolor sit amet ipso facto. [1] • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. • Lorem • Ipsum • Lorem ipsum dolor sit amet ipso: • Facto lorem ipso • Ramas cora dola tym • Foer tyr wuz • Hoccer • Lorem ipso dolor • Lorem ipsum dolor sit (Figure 1) • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto[8] Leu-Gly-Ala-Ser-Trp-His-Arg-Pro-Asp-Lys-Cys-Cys-Leu-Gly-Tyr-Gln-Lys-Arg-Pro-Leu-Pro-NH2 virokine L Figure 3. Virokine L EXPERIMENTAL METHODS Figure 5. Antagonist Activity Figure 1. Lorem ipsum dolor sit amet ipso facto (taken from [2]) Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipso hoccer foer tyr wuz de ras cora dola tymon ipso hoc cer fuz de ramas cora dola tymon ipso hoccer. Lorem ipso foer tyr wuz de ramas cora dola tym ipso hor.Lorem ipso foer tyr wuz de ramas cora dola tym ipso hor tyr wuz de ramas cora dola tymon ipso foer tyr wuz de ramas cora dola tymo. Lorem ipso hoccer foer tyr wuz de ras cora dola tymon ipso hoc cer fuz de ramas cora dola tymon ipso hoccer. Lorem ipso foer tyr wuz de ramas cora dola tym ipso hor. Lorem ipso foer tyr wuz de ramas cora dola tym ipso hor tyr wuz de ramas cora dola tymon ipso foer tyr wuz de ramas cora dola Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. CONCLUSIONS • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto[8] CXCR4 and Breast Cancer Metastasis REFERENCES • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto. [3] • Lorem ipsum dolor sit amet ipso facto.Lorem ipsum. [4] • Lorem ipsum dolor • Sit amet ipso facto • Lorem ipso foer tyr wuz de ramas • Lorem • Ipsum dolor facto (see Figure 2) • Facto Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto[3] foer tyr quz de ramas cora dola tym [5] facto.Lorem ipsum dolor sit amet ipso facto. Lorem ipsum dolor sit amet ipso facto.Lorem ipsum dolor sit amet ipso facto [1] Baggiolini, Dewald, Moser. Annu Rev Immunol,15, 675 (1997). [2] Lindow, Lüttichau, Schwartz. TIPS,24, 126 (2003). [3] Sehgal, Kenner, Boynton, Warrick, Murphy. J Surg Oncol, 69, 99 (1998). [4] Müller, Homey, Soto, Ge, Catron, Buchanan, McClanahan, Murphy, Yuan, Wagner, Barrera, Mohar, Verástegul, Zlotnik. Nature, 410, 50 (2001). [5] Tamamura, Hori, Kanzaki, Hiramatsu, Mizumoto, Nakashima, Yamamoto, Otaka, Fujii. FEBS Lett, 550, 79 (2003). [6] Liotta. Nature, 410, 24 (2001). [7] Kledal, Rosenkilde, Coulin, Simmons, Johnsen, Alouani, Power, Lüttichau, Gerstoft, Clapham, Clark-Lewis, Wells, Schwartz. Science, 277, 1656 (1997). [8] Zhou, Luo, Luo, Hall, Huang. Biochemistry, 39, 3782 (2000). [9] Amela-Cortés, Rezende, Wang, Papa, Perchellet, Perchellet, Vigil-Cruz. Biopolymers, Manuscript in Preparation. [10] Solé, Barany. J Org Chem, 57, 5399 (1995). [11] Cheng, Prusoff. Biochem Pharmacol, 22, 3099 (1973). RESULTS & DISCUSSION ACKNOWLEDGMENTS Table 2. CXCR4 Affinity of Ala Scan Analogues Analogue IC50(nM) Analogue IC50(nM) Analogue IC50(nM) • Funding • NIH COBRE award 1P20RR15563, and matching support from the State of Kansas and the University of Kansas (SVC) and NIH IRACDA award 5K12GM063651 (SVC) • Howard Hughes Medical Institute (Biological Sciences Education Grant) (JPP) and Kansas State University (Terry C. Johnson Center for Basic Cancer Research) (JPP) • Research Space and Equipment • Dr. Jane V. Aldrich, University of Kansas, Department of Medicinal Chemistry virokine L 123  3 [Ala7]virokine L 412  18 [Ala13]virokine L 15.8  0.8 [Ala1]virokine L 805  13 [Ala8]virokine L 194  11 [Ala14]virokine L 203  9 [Ala2]virokine L 466  23 [Ala9]virokine L 153  6 [Ala15]virokine L 93.9  2.5 [Ala4]virokine L 172  5 [Ala10]virokine L 419  10 [Ala16]virokine L 51.8  2.3 [Ala5]virokine L 75.7  3.3 [Ala11]virokine L 195  7 [Ala17]virokine L 257  16 Figure 2. Model of CXCR4 and SDF-1 Involvement in Metastasis (taken from [6]) [Ala6]virokine L 1,577  56 [Ala12]virokine L 190  8 [Ala18]virokine L 202  9